Rare Disease Preclinical Deal Benchmarks — US Only (2026)

Understanding Rare Disease Deal Benchmarks at Preclinical

Preclinical Rare Disease licensing deals in US Only territory command a median upfront payment of $26M, with values ranging from $8M at the low end to $48M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the rare disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $136M to $582M, with a median of $359M. Royalty rates for rare disease assets at this stage typically fall between 3.6% and 7.2% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.